BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11133737)

  • 1. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
    Zhang X; Wong R; Hao SX; Pear WS; Ren R
    Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
    Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
    Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
    Million RP; Van Etten RA
    Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
    Gross AW; Zhang X; Ren R
    Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
    Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
    Ilaria RL; Van Etten RA
    Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
    Jain SK; Susa M; Keeler ML; Carlesso N; Druker B; Varticovski L
    Blood; 1996 Sep; 88(5):1542-50. PubMed ID: 8781408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
    Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
    Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
    Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.